Mutual of America Capital Management LLC Purchases 5,245 Shares of Cencora, Inc. $COR

Mutual of America Capital Management LLC boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 26.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,065 shares of the company’s stock after buying an additional 5,245 shares during the period. Mutual of America Capital Management LLC’s holdings in Cencora were worth $7,834,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC lifted its stake in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the period. Caldwell Trust Co bought a new position in Cencora during the second quarter worth about $46,000. Salomon & Ludwin LLC boosted its holdings in Cencora by 638.1% during the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after purchasing an additional 134 shares in the last quarter. Finally, Capital A Wealth Management LLC grew its stake in shares of Cencora by 3,975.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after purchasing an additional 159 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on COR shares. Wells Fargo & Company raised their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Bank of America reduced their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. UBS Group lifted their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Robert W. Baird set a $415.00 price target on shares of Cencora in a research report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average target price of $393.08.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,316 shares of company stock worth $7,151,265 in the last quarter. Insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Cencora stock opened at $356.15 on Wednesday. The stock has a 50-day simple moving average of $348.17 and a 200 day simple moving average of $323.06. The stock has a market capitalization of $69.09 billion, a price-to-earnings ratio of 44.80, a P/E/G ratio of 1.69 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12-month low of $237.71 and a 12-month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.